使用iRGD作为瘤透的癌症治疗
Anbazhagan Thirumalai1, Koyeli Girigoswami1, Pragya Pallavi1
1Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Medical Bionanotechnology, Faculty of Allied Health Sciences, TN-603103 Kelambakkam, Chennai, India.
Bulletin du cancer
|October 9, 2023
概括
新型称为iRGD (CRGDK/RGPD/EC) 增强瘤透,改善癌症治疗和成像. 这些酸针对特定的受体,有效地将药物和成像剂更深入到瘤中.
科学领域:
- 在瘤学瘤学.
- 生物化学 生化学
- 纳米技术 纳米技术
背景情况:
- 瘤透率有限会降低癌症治疗中的疗效.
- 新型,包括iRGD (CRGDK/RGPD/EC),显示出增强的瘤透和抑制性质.
- iRGD可以向瘤血管和细胞上丰富的αvβ整合素 (αvβ3,αvβ5) 和NRP-1受体.
研究的目的:
- 审查iRGD在癌症治疗和成像中的最新进展和优势.
- 突出iRGD在改善药物输送和治疗结果方面的潜力.
- 强调iRGD在增强瘤透的作用,用于各种癌症疗法.
主要方法:
- 联合注射或iRGD与治疗剂,成像剂或免疫调节剂的化学结合.
- 用iRGD对纳米载体进行修改,以提供有针对性的有效载荷.
- 针对癌细胞治疗的iRGD驱动的双重向化疗剂的评估.
主要成果:
- iRGD可以促进治疗和成像剂深入瘤组织.
- 与传统相比,iRGD的简单合成.
- 显著改善瘤组织透率和有效抑制瘤转移.
- 已证明iRGD修饰的纳米载体在向更深的瘤区域输送有效载荷时的有效性.
结论:
- iRGD是一种有前途的策略,可以改善瘤治疗和成像.
- 它们能够准特定的受体并改善透的能力,与传统方法相比,具有显著的优势.
- 对iRGD驱动疗法的进一步研究有可能改善癌症患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
539
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539


